Why A Congressional Subpoena To Valeant About Price Gouging On Drugs Should Be Granted

Why A Congressional Subpoena To Valeant About Price Gouging On Drugs Should Be Granted by Citron Research

Short term price target $130 -- Longer Term … worse.

Note: This is part 1 in a multi-part story. While this note 1 discusses moral outrage over Valeant’s twisted strategic assault on the healthcare system, Part 2 will discuss the imminent danger of an over-levered balance sheet and why it will implode sooner than later.

Note: This is not a biotech problem. It is a Valeant problem.

The Real Risk to the US Healthcare System is when Health Care Costs are controlled by Hedge Fund Billionaires

How Pharmaceutical Pricing Runs Amok While U.S. Taxpayers Are Looted

For...